

1618
11/11
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
15727

In Re Application Of: **Helen G. Durk et al.**

DEC 03 2007

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/523,856	February 7, 2005	Unassigned	23389	1618	4411

Title:

A METHOD FOR MONITORING THE EFFECTIVENESS OF TETRACYCLINE IN THE TREATMENT OF ASTHMA

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
15727

In Re Application of: **Helen G. Durkin et al.**

DEC 03 2007

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/523,856	February 7, 2005	Unassigned	23389	1618	4411

Title:

A METHOD FOR MONITORING THE EFFECTIVENESS OF TETRACYCLINE IN THE TREATMENT OF ASTHMA

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

 (Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

November 30, 2007

 (Date)

Signature of Person Mailing Correspondence

Edward W. Grolz

Typed or Printed Name of Person Mailing Certificate

Dated: **November 30, 2007**

Edward W. Grolz

Reg. No. 33,705

Scully, Scott, Murphy & Presser, P.C.

400 Garden City Plaza

Suite 300

Garden City, NY 11530

(516) 742-4343

cc: **EWG/kl**

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
15727

In Re Application of: **Helen G. Durkin et al.**



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/523,856	February 7, 2005	Unsigned	23389	1618	4411

Title:

A METHOD FOR MONITORING THE EFFECTIVENESS OF TETRACYCLINE IN THE TREATMENT OF ASTHMA

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Edward W. Grolz

Reg. No. 33,705

Scully, Scott, Murphy & Presser, P.C.

400 Garden City Plaza

Suite 300

Garden City, NY 11530

(516) 742-4343

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

November 30, 2007

(Date)

Signature of Person Mailing Correspondence

Edward W. Grolz

Typed or Printed Name of Person Mailing Certificate

Dated: **November 30, 2007**

cc: **EWG/kl**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Helen G. Durkin, et al.

Examiner: Unassigned

Serial No: 10/523,856

Art Unit: 1618

Filed: February 7, 2005

Docket: 15727

For: A METHOD FOR MONITORING THE
EFFECTIVENESS OF TETRACYCLINE
IN THE TREATMENT OF ASTHMA

Dated: November 30, 2007

Confirmation No: 4411

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§1.56, 1.97 and 1.98

Sir:

Applicants, in order to meet their duty of disclosure, set forth at 37 C.F.R. §1.56, submit herewith those references which they deem relevant to the claims of the present application.


The relevant references are as follows:

1. Joks, et al., J. Allergy Clin. Immunol. 1998, 101:562
2. O'Dell, et al., Arthritis Rheum. 1997, 40:842-848
3. O'Dell, et al., Arthritis Rheum. 1999, 42:1691-1695
4. Yu, et al., Arthritis Rheum. 1992, 35:1150-1155

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 30, 2007.

Dated: November 30, 2007



Edward W. Grolz

5. Thong, et al., Clin Exp Immunol., 1979, 35:443-446
6. Ingham, et al., Antimicrob Chemother, 1991, 27:607-617
7. Amin, et al., PNAS, 1996, 93:14014-14019
8. U.S. Patent No. 6,309,669 dated October 30, 2001 (to Setterstrom et al.)
9. International Publication No. WO 03/099270 A1
10. U.S. Publication No. 2003/195184 dated October 16, 2003 (to Mitchell et al.)
11. International Publication No. WO 03/061767 A
12. International Publication No. WO 03/005971 A2
13. International Publication No. WO92/16226 A
14. Hahn, David L., Biodrugs, Auckland, NZ, vol. 14, 2000, pp. 349-354
15. Menon, M et al., Clinical And Experimental Allergy, Blackwell Scientific Publications, London, GB, vol. 7, 1997, pp. 285-290.

It is noted that the first seven references identified above are identified and discussed in the subject specification. Reference 8 was identified in an international search report issued in connection with the corresponding international application. A copy of said search report was filed with the application. A further copy is enclosed for the Examiner's convenience. The remaining seven references were recently identified in a search report issued in connection with the subject application's corresponding European application. A copy of said search report is also enclosed.


Applicants respectfully request that the above-mentioned references be made of record in the file of the present application. To that end, applicants submit herewith the aforementioned references and the completed Form PTO-1449, setting forth these references.

Applicants submit that the filing of this Information Disclosure Statement is prior to the issuance of a first office action on the merits. Therefore, no Declaration or fee is required to affect the filing of this Information Disclosure Statement.

Consideration of this Information Disclosure Statement is respectfully requested, since

the information provided herein may be material to the patentability of the subject application as defined in 37 C.F.R. §1.56.

Respectfully submitted,


Edward W. Grolz
Registration No. 33,705

Scully, Scott, Murphy & Presser
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343
EWG/kl